Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
暂无分享,去创建一个
C. Peng | Hao Chen | Haoda Chen | Xiaxing Deng | Baiyong Shen | Q. Zhan | Siyi Zou | N. Mou | Lingxi Jiang | Yan Jin | Q. Ai | Fanlu Li | Zehui Zhang | Chenlei Wen | Qi Ai | Fanlu Li | Siyi Zou | Y. Jin | Lingxi Jiang | Chenghong Peng | Nan Mou | Baiyong Shen | Qian Zhan
[1] Jun He,et al. Use of next‐generation sequencing to detect polymorphism of 11 HLA allele loci in the Chinese Han population and variance from other common and well‐documented lists , 2022, HLA.
[2] T. Shibata,et al. Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy , 2022, Cancer research.
[3] Marieke E. Ijsselsteijn,et al. A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer , 2022, Cancers.
[4] B. Fox,et al. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. , 2022, The New England journal of medicine.
[5] C. Chelala,et al. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy , 2022, Oncoimmunology.
[6] H. Ploegh,et al. A guide to antigen processing and presentation , 2022, Nature Reviews Immunology.
[7] TIL Transcriptomic States Enable Successful TCR Prediction. , 2022, Cancer discovery.
[8] V. Hoyos,et al. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects , 2022, Frontiers in Immunology.
[9] J. Gartner,et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers , 2022, Science.
[10] R. Hagedoorn,et al. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure , 2022, Oncoimmunology.
[11] Qiu-lin Tang,et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer , 2021, Molecular Cancer.
[12] Chenqi Xu,et al. Exploiting T cell signaling to optimize engineered T cell therapies. , 2021, Trends in cancer.
[13] A. Tsimberidou,et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors , 2021, Journal of Hematology & Oncology.
[14] Peiwen J. Ma,et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors , 2021, BMC Medicine.
[15] C. Cho,et al. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons , 2021, Frontiers in Immunology.
[16] G. Kvalheim,et al. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors , 2021, Oncoimmunology.
[17] Chun Jimmie Ye,et al. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer , 2020, Cell.
[18] M. Carrington,et al. Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Richardson,et al. Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms , 2020, Cancer Gene Therapy.
[20] Eric O Long,et al. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D , 2020, Proceedings of the National Academy of Sciences.
[21] M. Karamouzis,et al. Immunotherapy for pancreatic cancer: A 2020 update. , 2020, Cancer treatment reviews.
[22] Gang Yang,et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies , 2020, Molecular Cancer.
[23] T. Schumacher,et al. CD8+ T cell states in human cancer: insights from single-cell analysis , 2020, Nature Reviews Cancer.
[24] L. Buscail,et al. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer , 2020, Nature Reviews Gastroenterology & Hepatology.
[25] E. Wherry,et al. Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.
[26] J. Gartner,et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers , 2019, The Journal of clinical investigation.
[27] G. Coukos,et al. Safety and Tolerability of Adoptive Cell Therapy in Cancer , 2019, Drug Safety.
[28] Z. Siprashvili,et al. KRAS regulation by small non-coding RNAs and SNARE proteins , 2018, Nature Communications.
[29] J. Gartner,et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. , 2019, Cancer discovery.
[30] Douglas B. Johnson,et al. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer , 2018, Clinical Cancer Research.
[31] C. June,et al. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies , 2018, Clinical Cancer Research.
[32] Alexander H. E. Morrison,et al. Immunotherapy and Prevention of Pancreatic Cancer. , 2018, Trends in cancer.
[33] J. Gartner,et al. T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers , 2018, Clinical Cancer Research.
[34] Amal Paul,et al. Devil is in the detail , 2018, BMJ Case Reports.
[35] A. M. Houghton,et al. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma , 2018, The Journal of clinical investigation.
[36] Mithat Gönen,et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer , 2017, Nature.
[37] K. Haigis. KRAS Alleles: The Devil Is in the Detail. , 2017, Trends in cancer.
[38] S. Rosenberg,et al. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Gartner,et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.
[40] Shari Pilon-Thomas,et al. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors , 2016, Journal of Immunotherapy for Cancer.
[41] P. Sharma,et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial , 2016, The Lancet. Oncology.
[42] S. Rosenberg,et al. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy , 2016, Journal of immunotherapy.
[43] A. Wittinghofer,et al. Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down. , 2016, Cancer cell.
[44] D. Kranz,et al. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. , 2016, Trends in pharmacological sciences.
[45] M. Del Chiaro,et al. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer , 2016, Journal of immunotherapy.
[46] P. Sharma,et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial , 2016 .
[47] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[48] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[49] Michael B H Smith. Pros and cons …. , 2014, Evidence-based child health : a Cochrane review journal.
[50] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[51] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[52] D. Esposito,et al. Dragging ras back in the ring. , 2014, Cancer cell.
[53] K. Odunsi,et al. Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells , 2013, Cancer Immunology Research.
[54] Adam Bagg,et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.
[55] Bent K Jakobsen,et al. Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells , 2013, Science Translational Medicine.
[56] Y. Kanai,et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer , 2013, British Journal of Cancer.
[57] L. Zender,et al. T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.
[58] Xiang Du,et al. KRAS mutation testing in metastatic colorectal cancer. , 2012, World journal of gastroenterology.
[59] D. Munn,et al. Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. , 2012, Blood.
[60] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[61] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] R. Blasberg,et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.
[63] P. Muranski,et al. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma , 2010, The Journal of experimental medicine.
[64] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[65] H. Schmidt,et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] M. Jarvis,et al. Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL , 2005, Journal of Experimental Medicine.
[67] Guttorm Haraldsen,et al. Primary antitumor immune response mediated by CD4+ T cells. , 2005, Immunity.
[68] S. Rosenberg,et al. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[69] T. Oshikiri,et al. CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.
[70] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[71] Rong Wang,et al. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. , 2001, Trends in immunology.
[72] T. Blankenstein,et al. CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.
[73] R. Schreiber,et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .
[74] S. Rosenberg,et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.
[75] Stephen P. Schoenberger,et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.